Bharat Parenterals Limited Q1 FY26 results deck summary

Results deck of 28 Jul 2025, summarised by AI from the filing.

BPL maintains FY26 standalone revenue growth guidance of 12–14% and expects EBITDA margins of 15–17%, with Q1 FY26 standalone revenue at ₹94.37 cr.

Key takeaways

1. Q1 FY26 results Standalone revenue ₹94.37 cr (Q1 FY25: ₹92.06 cr, +2.51%); EBITDA ₹15.41 cr (Q1 FY25: ₹14.99 cr, +2.80%); PAT ₹10.00 cr (Q1 FY25: ₹12.18 cr, -17.90%).
2. Consolidated revenue growth Consolidated revenue from operations ₹116.00 cr (Q1 FY25: ₹92.51 cr, +25.4%), driven by Innoxel and Varenyam.
3. Growth driver Innoxel expected to generate ₹65–70 cr in FY26, with commercial CMO supplies anticipated to commence in Q1 FY27.
4. Key risk Innoxel facility is under construction and undergoing product validation; regulatory inspection anticipated by Q3 FY26.

Original filing on BSE

Bharat Parenterals Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Results deck (5 Aug 2026)
• Q4 FY26: Earnings call (19 May 2026), Results deck (18 May 2026)
• Q3 FY26: Results deck (30 Jan 2026)
• Q2 FY26: Earnings call (12 Nov 2025), Results deck (12 Nov 2025)
• Q1 FY26: Results deck (28 Jul 2025)
• Q4 FY25: Earnings call (14 May 2025)